NYSE:HEXO

HEXO Competitors

$5.52
-0.18 (-3.16 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.26
Now: $5.52
$5.60
50-Day Range
$5.70
MA: $6.74
$7.83
52-Week Range
$1.60
Now: $5.52
$11.04
Volume4.52 million shs
Average Volume6.74 million shs
Market Capitalization$676.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41

Competitors

HEXO (NYSE:HEXO) Vs. USNA, ACB, SNDL, CDXC, MDWD, and NAII

Should you be buying HEXO stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to HEXO, including USANA Health Sciences (USNA), Aurora Cannabis (ACB), Sundial Growers (SNDL), ChromaDex (CDXC), MediWound (MDWD), and Natural Alternatives International (NAII).

USANA Health Sciences (NYSE:USNA) and HEXO (NYSE:HEXO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

54.1% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 35.3% of HEXO shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for USANA Health Sciences and HEXO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
HEXO35402.08

USANA Health Sciences presently has a consensus target price of $126.00, indicating a potential upside of 27.41%. HEXO has a consensus target price of $4.1750, indicating a potential downside of 24.37%. Given USANA Health Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe USANA Health Sciences is more favorable than HEXO.

Valuation and Earnings

This table compares USANA Health Sciences and HEXO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42
HEXO$60.46 million11.18$-406,370,000.00($0.96)-5.75

USANA Health Sciences has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

USANA Health Sciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Profitability

This table compares USANA Health Sciences and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
HEXO-517.61%-13.15%-10.35%

Summary

USANA Health Sciences beats HEXO on 11 of the 14 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and HEXO (NYSE:HEXO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 35.3% of HEXO shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Aurora Cannabis and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
HEXO-517.61%-13.15%-10.35%

Valuation and Earnings

This table compares Aurora Cannabis and HEXO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76
HEXO$60.46 million11.18$-406,370,000.00($0.96)-5.75

HEXO has lower revenue, but higher earnings than Aurora Cannabis. HEXO is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aurora Cannabis and HEXO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
HEXO35402.08

Aurora Cannabis presently has a consensus target price of $10.9264, indicating a potential upside of 38.66%. HEXO has a consensus target price of $4.1750, indicating a potential downside of 24.37%. Given Aurora Cannabis' higher probable upside, equities analysts clearly believe Aurora Cannabis is more favorable than HEXO.

Risk & Volatility

Aurora Cannabis has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Summary

HEXO beats Aurora Cannabis on 9 of the 13 factors compared between the two stocks.

HEXO (NYSE:HEXO) and Sundial Growers (NASDAQ:SNDL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Profitability

This table compares HEXO and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXO-517.61%-13.15%-10.35%
Sundial Growers-415.89%-187.67%-72.67%

Valuation & Earnings

This table compares HEXO and Sundial Growers' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXO$60.46 million11.18$-406,370,000.00($0.96)-5.75
Sundial Growers$75.86 million18.54$-204,570,000.00($3.17)-0.27

Sundial Growers has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

35.3% of HEXO shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

HEXO has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, meaning that its stock price is 601% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for HEXO and Sundial Growers, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO35402.08
Sundial Growers32001.40

HEXO currently has a consensus target price of $4.1750, indicating a potential downside of 24.37%. Sundial Growers has a consensus target price of $0.7333, indicating a potential downside of 13.42%. Given Sundial Growers' higher probable upside, analysts clearly believe Sundial Growers is more favorable than HEXO.

Summary

Sundial Growers beats HEXO on 7 of the 13 factors compared between the two stocks.

ChromaDex (NASDAQ:CDXC) and HEXO (NYSE:HEXO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Profitability

This table compares ChromaDex and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChromaDex-39.86%-100.14%-50.35%
HEXO-517.61%-13.15%-10.35%

Valuation & Earnings

This table compares ChromaDex and HEXO's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChromaDex$46.29 million11.83$-32,150,000.00($0.52)-15.77
HEXO$60.46 million11.18$-406,370,000.00($0.96)-5.75

ChromaDex has higher earnings, but lower revenue than HEXO. ChromaDex is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

24.7% of ChromaDex shares are owned by institutional investors. Comparatively, 35.3% of HEXO shares are owned by institutional investors. 12.9% of ChromaDex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

ChromaDex has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for ChromaDex and HEXO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChromaDex00303.00
HEXO35402.08

ChromaDex presently has a consensus price target of $14.3333, indicating a potential upside of 74.80%. HEXO has a consensus price target of $4.1750, indicating a potential downside of 24.37%. Given ChromaDex's stronger consensus rating and higher possible upside, equities research analysts plainly believe ChromaDex is more favorable than HEXO.

Summary

ChromaDex beats HEXO on 8 of the 14 factors compared between the two stocks.

MediWound (NASDAQ:MDWD) and HEXO (NYSE:HEXO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Volatility and Risk

MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Profitability

This table compares MediWound and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediWound-53.12%-94.63%-29.86%
HEXO-517.61%-13.15%-10.35%

Analyst Ratings

This is a summary of recent recommendations for MediWound and HEXO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediWound00403.00
HEXO35402.08

MediWound presently has a consensus price target of $7.50, indicating a potential upside of 48.81%. HEXO has a consensus price target of $4.1750, indicating a potential downside of 24.37%. Given MediWound's stronger consensus rating and higher possible upside, equities research analysts plainly believe MediWound is more favorable than HEXO.

Valuation & Earnings

This table compares MediWound and HEXO's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediWound$31.79 million4.32$4.95 million$0.0863.00
HEXO$60.46 million11.18$-406,370,000.00($0.96)-5.75

MediWound has higher earnings, but lower revenue than HEXO. HEXO is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

16.0% of MediWound shares are owned by institutional investors. Comparatively, 35.3% of HEXO shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

HEXO (NYSE:HEXO) and Natural Alternatives International (NASDAQ:NAII) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for HEXO and Natural Alternatives International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO35402.08
Natural Alternatives International0000N/A

HEXO presently has a consensus price target of $4.1750, suggesting a potential downside of 24.37%. Given HEXO's higher possible upside, equities research analysts clearly believe HEXO is more favorable than Natural Alternatives International.

Profitability

This table compares HEXO and Natural Alternatives International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXO-517.61%-13.15%-10.35%
Natural Alternatives International0.40%0.71%0.43%

Institutional and Insider Ownership

35.3% of HEXO shares are held by institutional investors. Comparatively, 31.8% of Natural Alternatives International shares are held by institutional investors. 26.4% of Natural Alternatives International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares HEXO and Natural Alternatives International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXO$60.46 million11.18$-406,370,000.00($0.96)-5.75
Natural Alternatives International$118.88 million0.97$-1,640,000.00N/AN/A

Natural Alternatives International has higher revenue and earnings than HEXO.

Risk and Volatility

HEXO has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Natural Alternatives International has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Summary

Natural Alternatives International beats HEXO on 7 of the 12 factors compared between the two stocks.


HEXO Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89-2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88-1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85-1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
ChromaDex logo
CDXC
ChromaDex
1.3$8.20-4.0%$547.41 million$46.29 million-21.58
MediWound logo
MDWD
MediWound
1.4$5.04-2.0%$137.27 million$31.79 million-12.60Decrease in Short Interest
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$18.20-6.3%$115.72 million$118.88 million227.53High Trading Volume
Increase in Short Interest
Gap Up
HAPP
Happiness Biotech Group
0.6$1.84-0.5%$47.53 million$65.06 million0.00Increase in Short Interest
News Coverage
Mannatech logo
MTEX
Mannatech
1.3$19.13-2.4%$39.58 million$157.73 million5.89Gap Down
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.56-1.9%$29.89 million$190,000.00-0.35Increase in Short Interest
News Coverage
CYAN
Cyanotech
0.6$3.14-1.6%$19.15 million$31.90 million31.40
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.